Next Pharmaceuticals is pleased to announce that our placebo-controlled, double-blind clinical trial on Flavoxine has been published in Nutrition Journal, an open access, peer-reviewed, online journal. The published clinical trial is also available at PubMed and archived in PubMed Central.

The study reveals the multiple heart health benefits of Flavoxine. It clearly demonstrates that Flavoxine significantly reduces LDL-cholesterol and triglycerides, while decreasing blood pressure and fasting blood glucose. The study also shows that Flavoxine increases HDL cholesterol, and that it may be helpful in weight reduction, as the overweight individuals in the study lost an average of 5% of their body weight over an 8-week period.

Flavoxine would be a wonderful addition to your line of heart health products.  For more information, please contact Gary Lovell at 604-889-2249 or This e-mail address is being protected from spambots, you need JavaScript enabled to view it .